Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial
| Autor: | Mahboobeh, Safaeian, Carolina, Porras, Yuanji, Pan, Aimee, Kreimer, John T, Schiller, Paula, Gonzalez, Douglas R, Lowy, Sholom, Wacholder, Mark, Schiffman, Ana C, Rodriguez, Rolando, Herrero, Troy, Kemp, Gloriana, Shelton, Wim, Quint, Leen-Jan, van Doorn, Allan, Hildesheim, Ligia A, Pinto |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Costa Rica
Cancer Research viruses Enzyme-Linked Immunosorbent Assay Antibodies Viral Article Neutralization Virus-like particle Medicine Humans Papillomavirus Vaccines Vaccines Virus-Like Particle Papillomaviridae biology business.industry Viral Vaccine Papillomavirus Infections Vaccine trial Vaccine efficacy Virology Vaccination Titer Oncology Immunology Antibody Formation biology.protein Female Antibody business |
| Zdroj: | Cancer Prev Res (Phila) |
| ISSN: | 1940-6215 |
| Popis: | The Costa Rica HPV16/18 Vaccine Trial (CVT) showed that four-year vaccine efficacy against 12-month HPV16/18 persistent infection was similarly high among women who received one, two, or the recommended three doses of the bivalent HPV16/18 L1 virus-like particle (VLP) vaccine. Live-attenuated viral vaccines, but not simple-subunit vaccines, usually induce durable lifelong antibody responses after a single dose. It is unclear whether noninfectious VLP vaccines behave more like live-virus or simple-subunit vaccines in this regard. To explore the likelihood that efficacy will persist longer term, we investigated the magnitude and durability of antibodies to this vaccine by measuring HPV16- and HPV18-specific antibodies by VLP-ELISA using serum from enrollment, vaccination, and annual visits through four years in four vaccinated groups; one-dose (n = 78), two-doses separated by one month (n = 140), two doses separated by six months (n = 52), and three scheduled doses (n = 120, randomly selected). We also tested enrollment sera from n = 113 HPV16- or HPV18 L1-seropositive women prevaccination, presumably from natural infection. At four years, 100% of women in all groups remained HPV16/18 seropositive; both HPV16/18 geometric mean titers (GMT) among the extended two-dose group were non-inferior to the three-dose group, and ELISA titers were highly correlated with neutralization titers in all groups. Compared with the natural infection group, HPV16/18 GMTs were, respectively, at least 24 and 14 times higher among the two-dose and 9 and 5 times higher among one-dose vaccinees. Antibody levels following one-dose remained stable from month 6 through month 48. Results raise the possibility that even a single dose of HPV VLPs will induce long-term protection. Cancer Prev Res; 6(11); 1242–50. ©2013 AACR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|